C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - Wiley Online Library
The multitargeted tyrosine‐kinase inhibitor sunitinib has emerged as one of the standards of care for good‐and intermediate‐risk metastatic renal cell carcinoma. Although generally …
C Kollmannsberger, G Bjarnason, P Burnett, P Creel… - Oncologist, 2011 - hero.epa.gov
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good-and intermediate-risk metastatic renal cell carcinoma. Although generally …
C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - pubmed.ncbi.nlm.nih.gov
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good-and intermediate-risk metastatic renal cell carcinoma. Although generally …
C Kollmannsberger, G Bjarnason, P Burnett, P Creel… - The Oncologist, 2011 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good-and intermediate-risk …
C Kollmannsberger, G Bjarnason, P Burnett… - …, 2011 - search.ebscohost.com
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good and intermediate-risk metastatic renal cell carcinoma. Although generally …
C Kollmannsberger, G Bjarnason, P Burnett… - The …, 2011 - europepmc.org
The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good-and intermediate-risk metastatic renal cell carcinoma. Although generally …